Oncology Times

OncTimes Talk

Health EN ↓ 105 episodes

OncTimes Talk features a variety of podcast series ranging from breaking news and oncology conference coverage to story round-ups and in-depth interviews with current experts and leaders in oncology.

Be sure to visit the podcast's website and support the creator: journals.lww.com

Author

Oncology Times

Category

Health

Podcast website

journals.lww.com

Latest episode

Nov 10, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Episode 3, Better Informed Patient Journeys 05.03.2025

In the third episode of A Deep Dive Into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. David O'Malley, and Bobbie R, an ovarian cancer patient. Dr. O'Malley will highlight how HRD testing empowers ovarian cancer patients to make more informed decisions with their doctors to help guide their treatment journey, and Bobbie will provide in...

Episode 2, HRD Testing Deep-Dive 05.03.2025

In the second episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Erin Crane who will highlight how HRD testing provides helpful information to ovarian cancer patients.   Erin K. Crane, MD, MPH, is a gynecologic oncologist with Atrium Health Levine Cancer in Charlotte, North Carolina. A graduate of the SUNY Upstat...

Episode 1, A Precision Medicine Approach for Advanced Ovarian Cancer 05.03.2025

In the first episode of A Deep Dive into HRD Testing in Ovarian Cancer, a three-part podcast series sponsored by AstraZeneca, we're speaking with Dr. Kathleen Moore about HRD testing in ovarian cancer and its clinical significance in helping aid precision medicine approaches.   Dr. Kathleen Moore is a Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Associate...

Striking Microbiome Bacterial Population Differences Distinguish Metastatic Prostate Cancer From Non-Metastatic Disease 03.03.2025

At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patients.   After talking about his group's new data, lea...

Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer 03.03.2025

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer.   Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undetectable postoperative PSA did not significantly...

Novel Score Selects Patients With Intermediate Risk Prostate Cancer Safe for Active Surveillance 03.03.2025

A numerical formula called the absolute percentage pattern 4/5 (APP4) combining risk factors, including Gleason grade, PSA, and digital rectal examination, is being used to select patients whose intermediate risk prostate cancer can safely be followed with active surveillance.   A research study using APP4 was reported at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. First author...

Mobile Prostate Cancer Screening Clinic Raises Prostate Cancer Early Detection Rates in Underserved Communities 03.03.2025

Masood Moghul, MBBS, a urologist and research fellow at the Royal Marsden Hospital and Institute of Cancer Research in London, UK, discussed his group's findings from the Man Van study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients conducted in Greater London.   Moghul told the 2025 ASCO Genitourinary Cancers Symposium in San Francisco how...

KEYNOTE-006 Study 10-Year Survival Data Confirm PD-L1 Checkpoint Inhibition Best for Patients With Advanced Melanoma 25.01.2025

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the...

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 13.01.2025

Although one in five colorectal cancers having microsatellite instability and expressing the Werner Helicase (WRN) gene could be treated with drugs that inhibit WRN, the effectiveness of such an approach has been limited by resistance. However, researchers identified the Cys727 mutation as being solely responsible for WRN inhibitor resistance. This potentially opens the door to using WRN inhibitor...

Microsatellite Unstable Colorectal Cancers: Key Gene Mutation for Werner Helicase Inhibitor Resistance Identified 10.01.2025

The pivotal role of programmed death-ligand 1 (PD-L1) checkpoint inhibition for treating advanced melanoma has been confirmed in findings from the KEYNOTE-006 study comparing the anti-PD-L1 antibody pembrolizumab immunotherapy with the anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) drug ipilimumab for treating patients with unresectable advanced or metastatic melanoma. Results from the...

Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development 10.01.2025

A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location.   The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a   multidisciplinary team of interna...

Early Switch to Immunotherapy Recommended After BRAFV600 Mutation Targeted Therapy for Advanced Melanoma 10.01.2025

Findings from a study of patients receiving targeted therapy for their BRAFV600 mutation-positive advanced melanoma, suggest that switching early to immune checkpoint inhibition appeared to bring better rates of overall survival than saving immunotherapy for use as salvage treatment later on.   The ESMO 2024 Annual Congress heard from the randomized Phase II ImmunoCobiVem trial that a switch to im...

Clear Benefit From Early Checkpoint Inhibition in Locally Advanced, High-Risk Cervical Cancer 10.01.2025

A clinically meaningful benefit in overall survival was found in the second interim analysis of the randomized, double-blind, Phase III KEYNOTE-A18 study of immunotherapy together with concurrent chemoradiotherapy among 1,060 patients who had newly diagnosed, previously untreated high-risk locally advanced cervical cancer.   A multinational team of researchers, led from Italy, reported findings at...

The New Standard: Testing for All Therapy-Matched DNA and RNA Biomarkers Up Front 31.12.2024

In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in advanced cancer therapy selection. The two talk about the OncoExTra® test from Exact Sciences, which includes...

Digital Twin Brings AI Power to Individualize Cancer Management 25.12.2024

The prospect of markedly raising chemotherapy response rates and extending patient survival has been held out by scientists reporting a new AI-powered digital tool to optimize cancer management for individual patients.   The tool creates a "digital twin" for each patient that makes it possible to predict response to specific treatment regimens and confidently predict outcomes, according to finding...

Wnt Signaling Pathway Inhibitor Suggests Toxicity-Free Cure Potential for Hepatoblastoma 25.12.2024

The prospect of a minimally toxic, chemotherapy-free cure for hepatoblastoma is held out by findings from a mouse model using the small-molecule drug WNTinib that inhibits the Wnt signaling pathway involved with cancer growth.   Lead author Ugnė Balaševičiūtė, a pre-doctoral researcher in Translational Research of the Hepatic Oncology Group led by Josep M. Llovet, Professor at the Institut D'Inves...

Anti-HER2 Combination Found Effective in HER2-Altered Bile Duct Cancers 12.12.2024

A chemotherapy-free combination of two anti-human epidermal growth factor receptor 2 (anti-HER2) agents brought clinically meaningful responses to patients with bile duct cancers testing positive for HER2 or with mutated HER2 in research from Japan reported at the EORTC-NCI-AACR 2024 Molecular Targets and Cancer Therapeutics Symposium held in Barcelona, Spain.   In the SGNTUC-019 Phase II basket s...

FGFR-3 Inhibitor Has Early Clinical Activity in Advanced Urothelial Cancer 19.11.2024

The fibroblast growth factor receptor-3 (FGFR-3) inhibitor TYRA-300 has been found safe with dose-dependent responses and disease control in the Phase I SURF301 trial. The study included 41 patients who had been heavily pre-treated for their advanced solid tumors with activating FGFR3 mutations/fusions, bringing the hope of avoiding toxicities from the use of non-specific pan-FGFR inhibition.   Th...

Radiation Delivery by Mini Protein Brings Promise for Metastatic Urothelial & Other Solid Tumors 15.11.2024

The mini-protein radiopharmaceutical AKY-1189, designed to deliver the alpha-emitting isotope Actinium-225 (225Ac) to tumors expressing the Nectin-4 transmembrane protein, has been found to achieve favorable dosing to tumors, while minimizing exposure to non-target tissues, including the kidney. Data on the biodistribution and tumor uptake of the drug were reported at the 2024 EORTC-NCI-AACR 2024...

Antibody-Drug Conjugate "Promising Efficacy" in HER2-Positive and HER2-Low Breast Cancer 15.11.2024

In a Phase I study with 318 patients in China and Australia the antibody-drug conjugate (ADC) IBI354 was found to be safe and have promising efficacy in patients whose breast and other solid tumors tested positive for HER2 or were categorized as "HER2-low." At ESMO Congress 2024, the study also reported a low rate of interstitial lung disease in patients treated with the ADC. Oncology Times corres...

Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors 30.10.2024

Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO Congress 2024.   At the conference, Oncology Times...

Preoperative Chemoradiation Ruled Out for Gastric or GE Junction Resectable Adenocarcinoma 30.10.2024

The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding radiation before surgery in terms of overall or pro...

Perioperative Checkpoint Inhibition Better for Muscle-Invasive Bladder Cancer 30.10.2024

Patients with muscle-invasive bladder cancer experienced "clinically meaningful" improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy. This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Phase Ill trial of neoadjuvant durvalumab plus chemo...

Recurrent Glioma: Encouraging Responses to Autologous Myeloid Dendritic Cell Therapy 30.10.2024

When patients with recurrent high-grade glioblastoma were treated with autologous myeloid dendritic cells, they had clinical responses described as "encouraging" in a Phase I clinical trial reported at the ESMO Congress 2024. Cells harvested from each patient were injected directly into the resection cavity brain tissue lining after surgery. Patients also received intracranial injections of the ch...

Therapeutic mRNA Vaccine Brings New Hope in Glioblastoma 23.10.2024

Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona.   The CVGBM vaccine encodes multiple molecular features derived from tumor-associ...

Listen to the OncTimes Talk podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.